Quick Takeaways
- BML Investment Partners, L.P. filed SCHEDULE 13G/A for Aclaris Therapeutics, Inc. Common Stock, $0.00001 par value (ACRS).
- Disclosed ownership: 9.9%.
- Date of event: 23 Apr 2026.
BML Investment Partners, L.P. - 23 Apr 2026 SCHEDULE 13G/A Report for Aclaris Therapeutics, Inc. Common Stock, $0.00001 par value (ACRS)
- Filing Manager
- BML Investment Partners, L.P.
- Reporting Manager
- BML Investment Partners, L.P.
- Symbol
- ACRS
- Shares outstanding
- 140,909,091 shares
- Disclosed Ownership
- 13,950,000 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 27 Apr 2026, 19:26:18 UTC
- Date of event
- 23 Apr 2026
- Previous filing
- 09 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"BML Investment Partners, L.P. disclosed 9.9% ownership in Aclaris Therapeutics, Inc. Common Stock, $0.00001 par value (ACRS) on 23 Apr 2026."
What Changed
- Previous schedule filing date: 09 Feb 2026.
- Current filing was accepted on 27 Apr 2026, 19:26.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 9.9% | 13,950,000 | 0 | 13,950,000 | Braden M Leonard | BML Capital Management, LLC its General Partner By: Braden M Leonard, its Managing Member |